| Related Articles |
International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer: comment.
J Thromb Haemost. 2014 Mar 15;
Authors: Tendas A, Scaramucci L, Cupelli L, Lentini R, Trawinska MM, Giovannini M, Perrotti A, de Fabritiis P, Niscola P
Abstract
We read with great interest the paper by Farge et al, entitled "International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer" [1]; in particular, the "Special situations" section, in which the authors point out the difficulty in defining evidence-based guidelines in the setting of thromboembolism treatment or prophylaxis in thrombocytopenic cancer patients. Antithrombotic drugs are frequently used in clinical haematology, both for prophylaxis and for treatment of thrombotic complications. Moreover, home care (HC) managed patients with haematological disorders are frequently treated with antithrombotic drugs [2] due to the frequent presence of additional factors that increase thrombotic risk, such as active cancer [3], motor disability/bed resting [3], prothrombotic drug treatments and co-morbidities (e.g. atrial fibrillation). This article is protected by copyright. All rights reserved.
PMID: 24628812 [PubMed - as supplied by publisher]